^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Cervical Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
Published date:
09/27/2022
Excerpt:
Merck...announced that KEYTRUDA, Merck’s anti-PD-1 therapy, received four new approvals from Japan’s Ministry of Health, Labor and Welfare (MHLW):...KEYTRUDA in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with advanced or recurrent cervical cancer with no prior chemotherapy who are not amenable to curative treatment, based on data from the KEYNOTE-826 trial.
Secondary therapy:
Chemotherapy
Source:
Title:
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer Subgroup Analyses from the KEYNOTE-826 Randomized Clinical Trial
Published date:
12/14/2023
Excerpt:
The findings of this trial suggest that adding pembrolizumab to chemotherapy with or without bevacizumab improved OS across subgroups of patients with persistent, recurrent, or metastatic cervical cancer.
DOI:
10.1001/jamaoncol.2023.5410
Trial ID:
Source:
Title:
Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826
Published date:
05/26/2022
Excerpt:
Pembro + chemo ± bev prolonged PFS and OS vs pbo + chemo ± bev among the subgroups defined by bev use, histology, platinum use, and prior CRT and provided clinically meaningful benefits similar to the broader population of patients with persistent, recurrent, or metastatic cervical cancer.
Secondary therapy:
cisplatin + paclitaxel; carboplatin
DOI:
10.1200/JCO.2022.40.16_suppl.5506
Trial ID:
Source:
Title:
Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Persistent, Recurrent or Metastatic Cervical Cancer
Published date:
06/22/2021
Excerpt:
KEYTRUDA plus platinum-based chemotherapy with or without bevacizumab demonstrated statistically significant and clinically meaningful improvements in OS and PFS compared to the same platinum-based chemotherapy regimens with or without bevacizumab alone, regardless of PD-L1 status...
Secondary therapy:
carboplatin + paclitaxel; cisplatin + paclitaxel
Trial ID:
